A team of researchers led by the University of British Columbia (UBC) has reported the discovery of two chemical compounds that demonstrated strong antiviral effects across a wide range of viruses and protected mice from influenza A infection.
The findings were shared by UBC Science in a report published on February 6, 2026. The work highlights laboratory evidence of “potent and wide-ranging” antiviral activity and includes results from experiments in mice exposed to influenza A.
What the study found
According to the UBC Science report, the researchers identified two compounds that act as broad-spectrum antivirals. Broad-spectrum antivirals are designed to work against multiple viruses rather than targeting only one specific strain.
In the reported experiments, the compounds protected mice from influenza A infection. The report describes the antiviral activity as both strong and wide-ranging, indicating that the compounds were observed to work beyond a single virus in the research setting.
Why influenza A matters
Influenza A is a major cause of seasonal flu outbreaks and has been responsible for past pandemics. Research that explores treatments capable of addressing different viral threats is often aimed at improving readiness for outbreaks where rapid response is needed.
The UBC-led findings, as described, focus on compounds that could potentially offer a broader approach than therapies tailored to one virus type. The report, however, centres on study results in mice and laboratory assessments of antiviral activity.
What is known from the announcement
The UBC Science update states that the two compounds were newly discovered by the research team and showed powerful antiviral properties. It also states that these compounds protected mice from influenza A infection, a key result used to demonstrate potential effectiveness in a living organism.
No additional details were provided in the source summary regarding the compounds’ names, dosing, safety profile, or the next steps planned by the researchers.
Next steps
The report describes the discovery as a research finding from a UBC-led team. The information provided does not include timelines for further testing or whether clinical studies in humans are planned.
The publication underscores that the results involve protection in mice, which is commonly used as an early step in evaluating potential antiviral candidates before any consideration of human trials.